These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26142487)

  • 1. Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth.
    Chollet A; Mori G; Menendez C; Rodriguez F; Fabing I; Pasca MR; Madacki J; Korduláková J; Constant P; Quémard A; Bernardes-Génisson V; Lherbet C; Baltas M
    Eur J Med Chem; 2015 Aug; 101():218-35. PubMed ID: 26142487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
    Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical synthesis, biological evaluation and structure-activity relationship analysis of azaisoindolinones, a novel class of direct enoyl-ACP reductase inhibitors as potential antimycobacterial agents.
    Deraeve C; Dorobantu IM; Rebbah F; Le Quéméner F; Constant P; Quémard A; Bernardes-Génisson V; Bernadou J; Pratviel G
    Bioorg Med Chem; 2011 Nov; 19(21):6225-32. PubMed ID: 21975068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis.
    Matviiuk T; Madacki J; Mori G; Orena BS; Menendez C; Kysil A; André-Barrès C; Rodriguez F; Korduláková J; Mallet-Ladeira S; Voitenko Z; Pasca MR; Lherbet C; Baltas M
    Eur J Med Chem; 2016 Nov; 123():462-475. PubMed ID: 27490025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
    Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents.
    Menendez C; Chollet A; Rodriguez F; Inard C; Pasca MR; Lherbet C; Baltas M
    Eur J Med Chem; 2012 Jun; 52():275-83. PubMed ID: 22483635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Eur J Med Chem; 2014 Oct; 86():613-27. PubMed ID: 25218910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First triclosan-based macrocyclic inhibitors of InhA enzyme.
    Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
    Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
    Armstrong T; Lamont M; Lanne A; Alderwick LJ; Thomas NR
    Bioorg Med Chem; 2020 Nov; 28(22):115744. PubMed ID: 33007556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New coumarin linked thiazole derivatives as antimycobacterial agents: Design, synthesis, enoyl acyl carrier protein reductase (InhA) inhibition and molecular modeling.
    Kassem AF; Sabt A; Korycka-Machala M; Shaldam MA; Kawka M; Dziadek B; Kuzioła M; Dziadek J; Batran RZ
    Bioorg Chem; 2024 Sep; 150():107511. PubMed ID: 38870705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis.
    Matviiuk T; Mori G; Lherbet C; Rodriguez F; Pasca MR; Gorichko M; Guidetti B; Voitenko Z; Baltas M
    Eur J Med Chem; 2014 Jan; 71():46-52. PubMed ID: 24269516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
    am Ende CW; Knudson SE; Liu N; Childs J; Sullivan TJ; Boyne M; Xu H; Gegina Y; Knudson DL; Johnson F; Peloquin CA; Slayden RA; Tonge PJ
    Bioorg Med Chem Lett; 2008 May; 18(10):3029-33. PubMed ID: 18457948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
    Menendez C; Gau S; Lherbet C; Rodriguez F; Inard C; Pasca MR; Baltas M
    Eur J Med Chem; 2011 Nov; 46(11):5524-31. PubMed ID: 21944473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
    Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach.
    Kanetaka H; Koseki Y; Taira J; Umei T; Komatsu H; Sakamoto H; Gulten G; Sacchettini JC; Kitamura M; Aoki S
    Eur J Med Chem; 2015 Apr; 94():378-85. PubMed ID: 25778993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazoquinoline Derivatives as Potential Inhibitors of InhA Enzyme and
    Hoffmann P; Azéma-Despeyroux J; Goncalves F; Stamilla A; Saffon-Merceron N; Rodriguez F; Degiacomi G; Pasca MR; Lherbet C
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38999028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of phaitanthrin congeners as anti-mycobacterial agents.
    Kamal A; Reddy BV; Sridevi B; Ravikumar A; Venkateswarlu A; Sravanthi G; Sridevi JP; Yogeeswari P; Sriram D
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3867-72. PubMed ID: 26253635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
    Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
    Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data.
    Kuo MR; Morbidoni HR; Alland D; Sneddon SF; Gourlie BB; Staveski MM; Leonard M; Gregory JS; Janjigian AD; Yee C; Musser JM; Kreiswirth B; Iwamoto H; Perozzo R; Jacobs WR; Sacchettini JC; Fidock DA
    J Biol Chem; 2003 Jun; 278(23):20851-9. PubMed ID: 12606558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold.
    Pajk S; Živec M; Šink R; Sosič I; Neu M; Chung CW; Martínez-Hoyos M; Pérez-Herrán E; Álvarez-Gómez D; Álvarez-Ruíz E; Mendoza-Losana A; Castro-Pichel J; Barros D; Ballell-Pages L; Young RJ; Convery MA; Encinas L; Gobec S
    Eur J Med Chem; 2016 Apr; 112():252-257. PubMed ID: 26900657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.